公开(公告)号：US11718641B2

公开(公告)日：2023-08-08

申请号：US17186447

申请日：2021-02-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00 ,  C07J9/00 ,  C07J51/00

CPC classification number: C07J41/0066 ,  C07J41/0055 ,  C07J41/0088 ,  C07J43/003 ,  C07J43/006 ,  C07J9/005 ,  C07J41/0094 ,  C07J51/00

Abstract: The present invention provides compounds of Formula I,




pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US11560368B2

公开(公告)日：2023-01-24

申请号：US17197399

申请日：2021-03-10

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D403/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20220402966A1

公开(公告)日：2022-12-22

申请号：US17324464

申请日：2021-05-19

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Jiang Long ,  Peng Dai ,  Brett Granger ,  Jing He

IPC: C07J43/00 ,  C07J41/00 ,  C07J51/00 ,  C07J9/00

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US11040998B2

公开(公告)日：2021-06-22

申请号：US16593262

申请日：2019-10-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Jiang Long ,  Peng Dai ,  Brett Granger ,  Jing He

IPC: C07J43/00 ,  C07J41/00 ,  C07J9/00 ,  C07J51/00

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10968199B2

公开(公告)日：2021-04-06

申请号：US16546736

申请日：2019-08-21

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jing He ,  Brett Granger ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D401/14 ,  A61K31/444 ,  C07D401/04

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10683279B2

公开(公告)日：2020-06-16

申请号：US15979128

申请日：2018-05-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D403/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20190337923A1

公开(公告)日：2019-11-07

申请号：US16400529

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun MA ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D409/14 ,  C07D405/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20190194245A1

公开(公告)日：2019-06-27

申请号：US16222380

申请日：2018-12-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10323060B2

公开(公告)日：2019-06-18

申请号：US15439303

申请日：2017-02-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Xuechao Xing ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He

IPC: A61K31/575 ,  A61K31/58 ,  C07J9/00 ,  C07J43/00

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

公开(公告)号：US20180362503A1

公开(公告)日：2018-12-20

申请号：US15988806

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D471/04 ,  C07D471/08

CPC classification number: C07D401/14 ,  C07D417/14 ,  C07D451/02 ,  C07D451/06 ,  C07D471/04 ,  C07D471/08

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).